GlassScriptPhysician profile
Melissa Dang
NPI 1609453398
$1,171.22
in general payments reported to CMS, 2019-2025
8 companies · $789 in 2025
The $789 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $17.16 · 2023: $31.06 · 2024: $335 · 2025: $789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,154.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $371.44 | 2024-2025 | Airsupra, Fasenra |
| Biocryst US Sales Co., LLC | $222.52 | 2025 | Orladeyo |
| Genzyme Corporation | $166.89 | 2024-2025 | |
| Biocryst Pharmaceuticals, INC. | $150.80 | 2025 | Orladeyo |
| Pharming Healthcare, INC. | $124.87 | 2025 | Ruconest |
| Amgen INC. | $77.43 | 2022-2025 | Tezspire |
| Abbvie INC. | $31.06 | 2023 | Vraylar |
| Ionis Pharmaceuticals, INC. | $26.21 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Dang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.